Independent · clinically grounded · free

Plain answers about your GLP‑1, from the trials your doctor reads.

An index of weight loss projections, real costs, and dose schedules for Ozempic, Wegovy, Wegovy HD, Mounjaro, and Zepbound — calculated in your browser, from the published clinical‑trial endpoints. Nothing is sent anywhere.

Your weight isn't sent anywhere — not even to us.
02 — What the math is built on

Five trials. Cited every time we project a number.

No proprietary models. No telehealth partnerships. No marketing data. Only the published endpoints — the same ones your prescriber sees.

Trial · 2025

STEP UP

Semaglutide 7.2 mg (Wegovy HD) vs. 2.4 mg in adults with obesity. 72 weeks. −20.7% on HD dose.

NEJM 392:1501 ↗
Trial · 2021

STEP 1

Semaglutide 2.4 mg vs. placebo in overweight or obese adults without diabetes. 1,961 participants. 68 weeks.

NEJM 384:989 ↗
Trial · 2021

STEP 2

Semaglutide 2.4 mg in adults with type 2 diabetes and obesity. 1,210 participants.

Lancet 397:971 ↗
Trial · 2022

SURMOUNT-1

Tirzepatide 5/10/15 mg vs. placebo in obesity without diabetes. 2,539 participants. 72 weeks.

NEJM 387:205 ↗
Trial · 2021

SURPASS-2

Tirzepatide vs. semaglutide 1 mg in type 2 diabetes. 1,879 participants. 40 weeks.

NEJM 385:503 ↗
03 — Why this exists

Three reasons to use this instead of asking a chatbot or scrolling Reddit.

Your numbers stay on your phone.

No accounts. No cookies. No servers receiving your weight. The calculations run inside your browser tab. We genuinely can't see what you typed — there's nowhere for it to go.

We're not selling you a prescription.

No telehealth partnerships. No affiliate links inside the calculators. If we ever add affiliate links anywhere, they'll be labelled — and never inside the medical math.

Bring the printout to your appointment.

Every calculator exports a clean, doctor‑readable PDF. Walk in with the citations and your projection. Walk out with a plan you both understand.